FI962948A - Method for dissolving sparingly soluble pharmaceutically active substances - Google Patents

Method for dissolving sparingly soluble pharmaceutically active substances Download PDF

Info

Publication number
FI962948A
FI962948A FI962948A FI962948A FI962948A FI 962948 A FI962948 A FI 962948A FI 962948 A FI962948 A FI 962948A FI 962948 A FI962948 A FI 962948A FI 962948 A FI962948 A FI 962948A
Authority
FI
Finland
Prior art keywords
active substances
pharmaceutically active
sparingly soluble
soluble pharmaceutically
dissolving
Prior art date
Application number
FI962948A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI962948A0 (en
Inventor
Dadi Jamshed Dhabhar
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of FI962948A publication Critical patent/FI962948A/en
Publication of FI962948A0 publication Critical patent/FI962948A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI962948A 1994-01-24 1996-07-23 Process for dissolving difficult soluble pharmaceutically active substances FI962948A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18557694A 1994-01-24 1994-01-24
PCT/US1995/001018 WO1995019759A1 (en) 1994-01-24 1995-01-24 Process for solubilizing difficultly soluble pharmaceutical actives

Publications (2)

Publication Number Publication Date
FI962948A true FI962948A (en) 1996-07-23
FI962948A0 FI962948A0 (en) 1996-07-23

Family

ID=22681571

Family Applications (1)

Application Number Title Priority Date Filing Date
FI962948A FI962948A0 (en) 1994-01-24 1996-07-23 Process for dissolving difficult soluble pharmaceutically active substances

Country Status (14)

Country Link
EP (1) EP0741560A1 (en)
JP (1) JPH09508128A (en)
CN (1) CN1138827A (en)
AU (1) AU706890B2 (en)
BR (1) BR9506564A (en)
CA (1) CA2181241C (en)
CZ (1) CZ210496A3 (en)
FI (1) FI962948A0 (en)
MX (1) MX9602955A (en)
NO (1) NO963052L (en)
NZ (1) NZ279443A (en)
PL (1) PL315635A1 (en)
SK (1) SK96196A3 (en)
WO (1) WO1995019759A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998058637A1 (en) * 1996-06-20 1998-12-30 Mcneil-Ppc Acetaminophen and diphenhydramine analgesics
ZA975444B (en) * 1996-06-20 1998-12-21 Mcneil Ppc Inc Acetaminophen and meclizine hydrochloride analgesics
FR2751875B1 (en) * 1996-08-05 1998-12-24 Scr Newpharm NOVEL STABLE LIQUID FORMULATIONS BASED ON PARACETAMOL AND THEIR METHOD OF PREPARATION
US5763449A (en) * 1996-08-07 1998-06-09 Ascent Pediatrics, Inc. Pleasant-tasting aqueous liquid composition of a bitter-tasting drug
DE69940769D1 (en) * 1998-01-20 2009-06-04 Applied Analytical Ind Inc ORAL LIQUID COMPOSITIONS
US6365180B1 (en) * 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
US20020086878A1 (en) * 1999-01-11 2002-07-04 Douglas Joseph Dobrozsi Compositions having improved stability
US20020082307A1 (en) * 1999-01-11 2002-06-27 Dobrozsi Douglas Joseph Compositions having improved stability
US6846495B2 (en) 1999-01-11 2005-01-25 The Procter & Gamble Company Compositions having improved delivery of actives
US6211246B1 (en) * 1999-06-10 2001-04-03 Mcneil-Ppc, Inc. Rapidly absorbed liquid compositions
FR2796843B1 (en) * 1999-07-29 2003-05-09 So Ge Val Sa CONCENTRATED AND STABILIZED ANTIPYRETIC COMPOSITION FOR VETERINARY USE INTENDED TO BE INCORPORATED IN ANIMAL FEEDING AS WELL AS A METHOD OF INCORPORATING THIS COMPOSITION INTO ANIMAL BEVERAGE WATER
US6251426B1 (en) * 1999-09-02 2001-06-26 Banner Pharmacaps, Inc. Ibuprofen-containing softgels
DE10011032A1 (en) * 2000-03-07 2001-09-13 Bayer Ag Stable solutions of acetylsalicylic acid in mixture of organic solvent and water, useful for topical treatment of pain, especially pain associated with herpes zoster
KR20020069387A (en) * 2001-02-26 2002-09-04 진양제약주식회사 Mixing method of composition containing doxylamine succinate and soft capsule preparation containing the composition
JP2004538309A (en) * 2001-07-31 2004-12-24 ワイエス Sucralose formulation to mask unpleasant taste
US7101572B2 (en) * 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
CN100379406C (en) * 2003-09-22 2008-04-09 北京德众万全药物技术开发有限公司 Method for preparing tiny pellets of difficult soluble drugs and formulation containing the pellets
CA2627292C (en) * 2005-10-26 2012-04-17 Banner Pharmacaps, Inc. Hydrophilic vehicle-based dual controlled release matrix system
DE102005053066A1 (en) 2005-11-04 2007-05-10 Basf Ag Use of copolymers as solubilizers for sparingly water-soluble compounds
EP1962908A2 (en) * 2005-12-09 2008-09-03 Basf Se Use of polyvinyl lactam-polyoxyalkylene block copolymers as solubilisers for poorly water-soluble compounds
US8637076B2 (en) 2006-06-01 2014-01-28 Cima Labs Inc. Prednisolone salt formulations
JP2008184430A (en) * 2007-01-30 2008-08-14 Ss Pharmaceut Co Ltd Soft capsule
CA2690488C (en) * 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
CA2690490C (en) * 2010-01-19 2012-06-26 Accucaps Industries Limited Pharmaceutical formulations of loratadine for encapsulation and combinations thereof
EP3158991B1 (en) 2010-01-28 2021-03-17 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
WO2013142359A1 (en) 2012-03-20 2013-09-26 Eagle Pharmaceuticals, Inc. Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
DK2827862T3 (en) 2012-03-20 2024-02-12 Eagle Pharmaceuticals Inc FORMULATIONS OF BENDAMUSTINE
KR101695580B1 (en) * 2013-02-28 2017-01-13 화이자 인코포레이티드 Enhanced stability of novel liquid compositions
GB201506755D0 (en) * 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
TWI586379B (en) 2015-06-29 2017-06-11 永信藥品工業股份有限公司 Method of preparing very slightly soluble drug with solid dosage form
WO2017062997A1 (en) 2015-10-09 2017-04-13 Reckitt Benckiser Llc Pharmaceutical formulation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141961A (en) * 1991-06-27 1992-08-25 Richrdson-Vicks Inc. Process for solubilizing difficulty soluble pharmaceutical actives

Also Published As

Publication number Publication date
SK96196A3 (en) 1997-03-05
NO963052L (en) 1996-09-24
EP0741560A1 (en) 1996-11-13
WO1995019759A1 (en) 1995-07-27
NZ279443A (en) 1998-04-27
BR9506564A (en) 1997-09-02
CA2181241A1 (en) 1995-07-27
MX9602955A (en) 1997-06-28
CZ210496A3 (en) 1996-12-11
FI962948A0 (en) 1996-07-23
CN1138827A (en) 1996-12-25
PL315635A1 (en) 1996-11-25
AU706890B2 (en) 1999-07-01
JPH09508128A (en) 1997-08-19
NO963052D0 (en) 1996-07-22
AU1607595A (en) 1995-08-08
CA2181241C (en) 2000-04-25

Similar Documents

Publication Publication Date Title
FI962948A (en) Method for dissolving sparingly soluble pharmaceutically active substances
NO961136D0 (en) Pharmaceutical formulation basis for nano-suspensions
FI946173A0 (en) A method for improving the efficacy of drug delivery using modified saponins
NO20010556L (en) Procedure for ophthalmic administration
EE9800116A (en) Pharmaceutically active quinazoline compounds
KR970006279A (en) 6-Dimethylaminomethyl-1-phenyl-cyclohexane compound as active pharmaceutical ingredient
DE69525148D1 (en) PHARMACEUTICAL FORMULATION
DE69514087D1 (en) PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS
BR9504060A (en) Compound and pharmaceutical formulation
DK0780369T3 (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutically active substances
NO974618D0 (en) Pharmaceutical preparations for intranasal administration
DE69513671D1 (en) DRUG
NO984106D0 (en) Azolobenzazepine derivatives as neurologically active agents
NO980546D0 (en) Pharmaceutical agents
BR9610396A (en) Pharmaceutical formulation
FI961437A0 (en) Active substance delivery system
BR9708949A (en) Compound pharmaceutical formulation and processes for preparing them and treating a mammal including man
DK0868911T3 (en) Rapamycin preparations for oral administration
ITMI940506A0 (en) CHINZOLILAMINIC DERIVATIVES ACTIVE AS ALPHA-ANTAGONISTS
FI943201A (en) Active substance delivery device
NO950134D0 (en) Formulations for orally administered pharmaceutical agents
EE9400296A (en) Piperidinylthioindole derivatives, dosage forms, active analgesic, methods for their preparation
DE69528843D1 (en) PHARMACOLOGICALLY ACTIVE 2-MERCAPTOBENZIMIDAZOLE DERIVATIVES
FI973963A (en) Method and arrangement for calibrating the active filter
IS5062A (en) Medicinal preparations containing N-sulfonylindoline derivatives